Comment on the draft revised Guidance document: Switching a medicinal ingredient from prescription to non-prescription status

Current status: Open

Opened on April 21, 2022 and will close to new input on June 20, 2022.

Health Canada has updated the current guidance document for companies who wish to submit a request for a change from prescription to non-prescription status to:

For more information, please see the accompanying notice.

How to participate

Review the draft revised guidance document: Switching a medicinal ingredient from prescription to non-prescription status

Send us your input by email to policy_bureau_enquiries@hc-sc.gc.ca.

Who is the focus of this consultation?

Health Canada wants to hear from:

Goals of the consultation

We are seeking comments from industry and any other interested parties on the usefulness and clarity of the draft revised guidance document. We will use input gathered from this consultation to improve and finalize the document.

Related information

Contact us

Bureau of Policy, Science and International Programs
Therapeutic Products Directorate
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C5
Ottawa ON  K1A 0K9

Email: policy_bureau_enquiries@hc-sc.gc.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: